171 related articles for article (PubMed ID: 21274948)
1. Double targeting of tumours with pyrenyl-modified dendrimers encapsulated in an arene-ruthenium metallaprism.
Pitto-Barry A; Barry NP; Zava O; Deschenaux R; Dyson PJ; Therrien B
Chemistry; 2011 Feb; 17(6):1966-71. PubMed ID: 21274948
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of cytotoxicity by combining pyrenyl-dendrimers and arene ruthenium metallacages.
Pitto-Barry A; Zava O; Dyson PJ; Deschenaux R; Therrien B
Inorg Chem; 2012 Jul; 51(13):7119-24. PubMed ID: 22716166
[TBL] [Abstract][Full Text] [Related]
3. Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage.
Furrer MA; Schmitt F; Wiederkehr M; Juillerat-Jeanneret L; Therrien B
Dalton Trans; 2012 Jun; 41(24):7201-11. PubMed ID: 22506276
[TBL] [Abstract][Full Text] [Related]
4. Drug delivery of lipophilic pyrenyl derivatives by encapsulation in a water soluble metalla-cage.
Mattsson J; Zava O; Renfrew AK; Sei Y; Yamaguchi K; Dyson PJ; Therrien B
Dalton Trans; 2010 Sep; 39(35):8248-55. PubMed ID: 20689885
[TBL] [Abstract][Full Text] [Related]
5. Delivery of floxuridine derivatives to cancer cells by water-soluble organometallic cages.
Yi JW; Barry NP; Furrer MA; Zava O; Dyson PJ; Therrien B; Kim BH
Bioconjug Chem; 2012 Mar; 23(3):461-71. PubMed ID: 22263930
[TBL] [Abstract][Full Text] [Related]
6. Excellent correlation between drug release and portal size in metalla-cage drug-delivery systems.
Barry NP; Zava O; Dyson PJ; Therrien B
Chemistry; 2011 Aug; 17(35):9669-77. PubMed ID: 21735491
[TBL] [Abstract][Full Text] [Related]
7. Encapsulation of pyrene-functionalized poly(benzyl ether) dendrons into a water-soluble organometallic cage.
Pitto-Barry A; Barry NP; Zava O; Deschenaux R; Therrien B
Chem Asian J; 2011 Jun; 6(6):1595-603. PubMed ID: 21626704
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, characterisation and in vitro anticancer activity of hexanuclear thiolato-bridged arene ruthenium metalla-prisms.
Furrer MA; Garci A; Denoyelle-Di-Muro E; Trouillas P; Giannini F; Furrer J; Clavel CM; Dyson PJ; Süss-Fink G; Therrien B
Chemistry; 2013 Feb; 19(9):3198-203. PubMed ID: 23344898
[TBL] [Abstract][Full Text] [Related]
9. Arene ruthenium complexes as anticancer agents.
Süss-Fink G
Dalton Trans; 2010 Feb; 39(7):1673-88. PubMed ID: 20449402
[TBL] [Abstract][Full Text] [Related]
10. Ruthenium polypyridine complexes of tris-(2-pyridyl)-1,3,5-triazine-unusual building blocks for the synthesis of photochemical molecular devices.
Schwalbe M; Karnahl M; Görls H; Chartrand D; Laverdiere F; Hanan GS; Tschierlei S; Dietzek B; Schmitt M; Popp J; Vos JG; Rau S
Dalton Trans; 2009 May; (20):4012-22. PubMed ID: 19440601
[TBL] [Abstract][Full Text] [Related]
11. Ruthenium dendrimers against acute promyelocytic leukemia:
Michlewska S; Ionov M; Maroto-Díaz M; Szwed A; Ihnatsyeu-Kachan A; Abashkin V; Dzmitruk V; Rogalska A; Denel M; Gapinska M; Shcharbin D; Gomez Ramirez R; de la Mata FJ; Bryszewska M
Future Med Chem; 2019 Jul; 11(14):1741-1756. PubMed ID: 31287722
[TBL] [Abstract][Full Text] [Related]
12. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
Ruiz J; Vicente C; de Haro C; Bautista D
Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
[TBL] [Abstract][Full Text] [Related]
14. Experimental and computational evidence for an inversion in guest capacity in high-generation triazine dendrimer hosts.
Lim J; Pavan GM; Annunziata O; Simanek EE
J Am Chem Soc; 2012 Feb; 134(4):1942-5. PubMed ID: 22239724
[TBL] [Abstract][Full Text] [Related]
15. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
[TBL] [Abstract][Full Text] [Related]
16. Thiophenolato-bridged dinuclear arene ruthenium complexes: a new family of highly cytotoxic anticancer agents.
Gras M; Therrien B; Süss-Fink G; Zava O; Dyson PJ
Dalton Trans; 2010 Nov; 39(42):10305-13. PubMed ID: 20890536
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
[TBL] [Abstract][Full Text] [Related]
18. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
[TBL] [Abstract][Full Text] [Related]
19. Anticancer activity of opened arene ruthenium metalla-assemblies.
Barry NP; Zava O; Furrer J; Dyson PJ; Therrien B
Dalton Trans; 2010 Jun; 39(22):5272-7. PubMed ID: 20442944
[TBL] [Abstract][Full Text] [Related]
20. Ruthenium(II)-arene complexes with functionalized pyridines: synthesis, characterization and cytotoxic activity.
Grgurić-Sipka S; Ivanović I; Rakić G; Todorović N; Gligorijević N; Radulović S; Arion VB; Keppler BK; Tesić ZLj
Eur J Med Chem; 2010 Mar; 45(3):1051-8. PubMed ID: 20053483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
